Raising awareness for the sarcoma cancer chordoma.
- Bill Number
- H.Res. 172
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-27: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-07T20:36:15Z
AI-Generated Summary
Purpose of the Legislation
This House Resolution (H. Res. 172) aims to raise awareness about chordoma, a rare and aggressive form of bone cancer that affects the skull and spine. It expresses the House of Representatives' support for increased funding and resources to improve diagnosis, treatment, and research for this disease.
Key Provisions
- Description of Chordoma: The resolution outlines chordoma as a slow-growing but aggressive cancer that impacts people of all ages, affecting over 25,000 individuals worldwide, with about 300 new diagnoses annually in the United States.
- Challenges in Treatment: It highlights the complexity of treating chordomas due to their location near critical body parts like the brain stem, spinal cord, nerves, and arteries. While surgery and radiation can be effective for some, recurrence rates are high, and no drugs currently exist to cure or control the disease effectively.
- Sense of the House: The resolution declares that chordoma patients and their families require greater support in four areas:
- Accurate and early diagnosis.
- Development of new treatments, diagnostic tools, and potential cures.
- Reducing barriers between research and the availability of new treatments.
- Adopting patient-focused methods in drug discovery and development.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no changes to existing laws or statutes. It serves as an expression of congressional opinion rather than enforceable legislation.
Potential Impacts
- On Citizens: Could increase public and medical awareness of chordoma, potentially leading to earlier diagnoses and better access to specialized care for the roughly 300 U.S. patients diagnosed yearly. It may encourage more research funding, offering hope to patients facing limited treatment options.
- On Government Agencies: May prompt agencies like the National Institutes of Health (NIH) or the Food and Drug Administration (FDA) to prioritize chordoma-related research and streamline approvals for new therapies, though no direct mandates are included.
- On International Relations: Minimal impact, but it could foster global collaboration on chordoma research given the disease's worldwide prevalence (over 25,000 affected).
Main Stakeholders Affected
- Patients and Families: Primary beneficiaries, as the resolution advocates for better diagnostics, treatments, and support to address high recurrence rates and lack of curative drugs.
- Healthcare Providers and Researchers: Benefits specialists in oncology and neurosurgery, as well as scientists working on rare cancers, by calling for reduced hurdles in research-to-treatment pipelines.
- Advocacy Groups and Non-Profits: Organizations focused on sarcoma or rare diseases may gain visibility and leverage the resolution to push for funding.
- Government and Policymakers: Members of Congress and health agencies are indirectly involved through the call for increased funding and patient-centric approaches.
Notable Legal, Constitutional, or Political Implications
- Legal: None, as resolutions like this are symbolic and do not create legal obligations or alter statutes.
- Constitutional: No implications, as it falls within Congress's broad authority to express opinions on public health matters without infringing on individual rights.
- Political: Demonstrates bipartisan support (introduced by representatives from both parties) for rare disease awareness, potentially influencing future appropriations bills or health policy debates. It underscores the role of Congress in advocating for underserved medical conditions without partisan controversy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Johnson, Henry C. "Hank" [D-GA-4]
Cosponsors (4)
Rep. McBath, Lucy [D-GA-6], Rep. Wilson, Frederica S. [D-FL-24], Rep. Velázquez, Nydia M. [D-NY-7], Del. Norton, Eleanor Holmes [D-DC-At Large]
Recent Actions
- 2025-02-27: Referred to the House Committee on Energy and Commerce.
- 2025-02-27: Submitted in House
Bill Versions
- Raising awareness for the sarcoma cancer chordoma. — issued 2025-02-27 — PDF (2 pages)